isolated B. fragilis are -lactamase producers. Most of the enzymes are chromosomally mediated cephalosporinases, with activities against many narrow-and broad-spectrum penicillins and cephalosporins. These enzymes are inhibited by -lactamase inhibitors and were assigned to group 2e and molecular class A, 4 being encoded by chromosomal 5 or rarely plasmid 6 cepA gene. So, the preferred -lactams for treatment of B. fragilis-associated infections include cefoxitin, -lactams/ -lactamase inhibitor combinations and carbapenems. However, more recently an enzyme encoded by cfxA gene, 7 which confers resistance to cefoxitin among strains of the B. fragilis group has been described, but its expression seems to be rare. Moreover, the production of a metallo--lactamase by B. fragilis strains has compromised the clinical use of cefoxitin and more recently of carbapenems. This enzyme, encoded by the chromosomal 8 or plasmid 9 cfiA gene, and belonging to molecular class B and functional group 3, 4 hydrolyses a broad spectrum of -lactams, including cephamycins and carbapenems. The cfiA-type metallo--lactamase has only been reported in B. fragilis strains isolated from clinical specimens in the USA, 10 France 11 and the UK, 12 maybe because it has been demonstrated that a small number of B. fragilis strains (2.4%) carry a silent metallo--lactamase gene, 13 which requires migration of an insertion sequence upstream of the -lactamase gene for its expression.
14 In addition, the widespread use of imipenem and, more recently, of meropenem can be an important selective pressure. 15 The purpose of the present study was to determine the antimicrobial resistance profile of B. fragilis strains isolated from clinical specimens in two periods (1981-1988 and 1991-1998 ) in a Brazilian University hospital, so that trends in the emergence of resistance could be detected. Strains from human intestinal microflora and polluted aquatic environments were also included in this study as an indicator of the use of antibiotics by the community. Finally, the presence of the metallo--lactamase gene, cfiA, has also been investigated.
Materials and methods

Bacterial strains
A total of 78 strains of B. fragilis, including 44 clinical strains, 17 strains isolated from human intestinal microflora and 17 strains from polluted aquatic environments were analysed. The clinical specimens were collected in two periods (1981-1988 and 1991-1998 ) from patients at the University hospital (Federal University of Rio de Janeiro-HU-UFRJ) in Brazil. The strains from the 1981-1988 period were stored at Ϫ70°C in 20% skimmed milk (BBL Microbiology Systems, Cockeysville, MD, USA). Human intestinal B. fragilis strains were isolated from normal individuals who agreed to the use of their excrement, which was collected in PYG-bile, 16 between 1991 and 1998. The environmental strains were collected from polluted aquatic environments at sewage plants, polluted rivers and an artesian well during the same period. Strains from polluted aquatic environments were isolated after sample collection (300 mL) in sterile flasks containing 0.05% sodium thioglycolate (Difco Laboratories, Detroit, MI, USA) and 0.15% cysteine hydrochloride (Sigma Chemical Co, St Louis, MO, USA), centrifuged at 6000g for 60 min and the sediment inoculated on PYG-bile with gentamicin (Schering-Plough, Rio de Janeiro, RJ, Brazil) 0.2 g/L (37°C/24 h) for B. fragilis enrichment. All specimens were plated on to Bacteroides bile aesculin agar-BBE. 17 Suspect organisms were transferred to brain heart infusion broth (Difco) (pre-reduced anaerobically sterilized, BHI-PRAS) 16 and were identified by established methodology. 18 The strains were stored at Ϫ70°C in skimmed milk.
Antimicrobial susceptibility testing
Antimicrobial susceptibility tests against penicillin, cefoxitin, imipenem, meropenem, clindamycin, chloramphenicol and metronidazole were performed by Etest method (AB Biodisk, Dalvägen, Solna, Sweden) according to the manufacturer's instructions. The inoculum (10 8 cfu/mL) in Brucella broth (BBL) was applied with a sterile cotton swab on Wilkins-Chalgren (Difco) enriched with 5% defibrinated sheep blood. 19 NCCLS breakpoints were used for susceptibility categorization. 20 Nitrocefin discs (BBL) were inoculated with a small portion of growth from culture on blood agar plates (Oxoid Ltd, Basingstoke, UK), supplemented with haemin (Sigma) and menadione (Sigma) and any colour change from yellow to red in 15 to 30 min at 37°C observed. Reference strain ATCC 25285 of B. fragilis (American Type Culture Collection, Rockville, MD, USA) was included in both experiments to assess the reliability of the methods.
Statistical analysis
Fisher's exact test 21 was used to compare the results obtained with the B. fragilis strains analysed. All significant differences were reported at the 95% CI (P Ͻ 0.05).
Polymerase chain reaction investigation of cfiA
For DNA extraction, cells from broth cultures (5 mL) in the logarithmic phase were harvested by centrifugation at 13000g for 1 min. The discarded and individual cell pellets was stored at Ϫ20°C without additional treatment until DNA isolation. Pure genomic DNA from all strains tested was obtained by a standard miniprep procedure 22 to which a ribonuclease A (Sigma) treatment was added. 23 The concentration of DNA in the samples was determined spectrophotometrically using GenQuant apparatus (Pharmacia Biotech, Björkgata, Uppsala, Sweden). For the cfiA investigation the primers used had the sequence of nucleotides the complementary sequence of nucleotides 1266 to 1285 (5Ј-GGGCTATGGCTTTGAAGTGC-3Ј) 11 of the cfiA gene.
8 These primers were obtained from Gibco BRL (Grand Island, NY, USA). Fifty nanograms of DNA template were used per reaction. The amplification was carried out in a 25 L volume containing 80 pmol of each primer, 200 M deoxynucleoside triphosphates mixture (Gibco BRL), PCR buffer (Gibco BRL) (200 mM Tris-HCl (pH 8.4), 500 mM KCl), 50 mM MgCl 2 (Gibco BRL), and 1.25 U Taq DNA polymerase (Gibco BRL). The PCR mixtures were overlaid with mineral oil (M 3516; Sigma). Temperature cycling was controlled in a model PTC-100 (Peltier-Effect Cycling, Watertown, MA, USA) and programmed as following: 30 cycles of 1 min at 92°C, 2 min at 62°C, 2 min at 72°C with a final extension time of 5 min at 72°C. The samples (10 L) were analysed by electrophoresis in 1% agarose gels (Gibco, BRL) in Trisacetate buffer (Gibco, BRL) (0.04 M Tris-acetate, 0.002 M EDTA, pH 8.5), stained with ethidium bromide (Sigma) and photographed on a UV light transilluminator using the 'Polaroid MP4' system (St Albans, UK). A molecular weight standard (1 kb DNA ladder, Gibco BRL) was included.
Results
The results of the susceptibility tests of clinical, intestinal and environmental strains are summarized in Tables I, II and III, respectively. In the two periods (1981-1988 and 1991-1998 ) a high rate of resistance to penicillin among clinical isolates was observed (Table I) . However, the MIC 90 decreased significantly from the first to the second period. In contrast, an increased rate of resistance to cefoxitin was seen from the first period to the second among the clinical isolates. All the strains studied were -lactamase producers confirming the universal presence of this enzyme in B. fragilis. All clinical isolates were susceptible to imipenem and meropenem. However, two strains, from intra-abdominal infections, showed intermediate resistance to meropenem (MIC 6 mg/L and 8 mg/L).
The cfiA investigation by PCR generated a fragment corresponding in size to the cfiA gene in the clinical strains a NCCLS (1997). levels of resistance against cefoxitin (32 mg/L and 64 mg/L), penicillin (6 mg/L and 12 mg/L) and clindamycin (8 mg/L and Ͼ256 mg/L). An increase was seen in the rate of resistance to clindamycin from the first period analysed (7.1%) to the second period (26.7%). Strains resistant to chloramphenicol were not found during the two periods analysed. Also, there were no strains resistant to metronidazole, with MIC 90 in both periods much lower than the breakpoint as established by NCCLS.
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Strains from human intestinal microbiota and polluted aquatic environments (Tables II and III) showed high resistance rates to penicillin and clindamycin, moderate rates of resistance to cefoxitin and no resistance to imipenem, meropenem, chloramphenicol and metronidazole. The exceptions were one strain from a polluted river (SPA-2) against which the MIC of cefoxitin was 64 mg/L and that of meropenem was Ͼ32 mg/L, and another strain from an artesian well (AA10), against which the MIC meropenem was 6 mg/L (considered 'intermediate' by NCCLS 20 ) The cfiA gene was detected ( Figure 2 ) by PCR in these two strains and another strain susceptible to meropenem (AA7b) from a polluted river.
Discussion
In Brazil, susceptibility testing of anaerobic bacteria is rarely done. This report investigated the trends in resistance to the main antimicrobial agents traditionally used in the management of anaerobic infections, since different rates among medical institutions have been reported as a consequence of differing use of antibiotics. 24, 25 Nowadays, clindamycin and metronidazole are extensively used as empirical therapy in surgical wards at the HU-UFRJ. This may explain the increase in the rate of resistance to clindamycin among clinical isolates observed from the first period to the second analysed, although the difference found is not significant. Dubreuil et al. 26 have shown similar results, in a retrospective survey in France (1977 to 1992), with a range from 1% to a peak of 19% up to 1988. Recently, Breuil and co-workers 27 have asserted that similar rates to clindamycin and tetracycline can be detected in different geographical regions. These results need to be interpreted with caution, as different methodology has been used, particularly for clindamycin, where differences can occur between the conventional agar dilution test and the Etest. 19 Metronidazole had consistently good activity, ratifying the concept that a uniform sensitivity of B. fragilis to this antimicrobial agent is expected, 28,29 although a few reports of resistant strains can be found in the literature.
30,31
Chloramphenicol showed results as good as metronidazole, in spite of the fact that it was frequently used during the first period (1981) (1982) (1983) (1984) (1985) (1986) (1987) (1988) ) to treat patients with anaerobic infections in the University hospital (personal communication, 1998). The resistance rate observed for cefoxitin in the last period (6.7%) can be attributed to the relatively low use of this specific agent in the HU-UFRJ, although the MIC 90 increased four-fold from the first to the second period. Lower rates (1.9%) for cefoxitin had been detected by our group in bacterial isolates from another different medical centre. 29 Such data reinforce the possibility of variation in susceptibility profiles between institutions, and emphasize the importance of monitoring, especially in countries where the treatment of anaerobic infections is empirical. In this study, the resistance to penicillin and clindamycin among intestinal and environmental strains seems to be linked to the oral form of administration of these drugs. On the other hand, as cefoxitin is marketed only in intravenous form, its use is more restricted to the hospital environment. So, these results also seem to ratify the correlation between drug consumption and the emergence of bacterial drug resistance among colonic bacteria.
Bacteroides as well as Gram-positive bacteria are numerically predominant in the human colon and may act as important reservoirs for resistance genes, potentially transferable directly or indirectly to human pathogens. 2 In addition, transfer of antibiotic resistance genes in the natural environment can occur between phylogenetically distant bacteria, in particular between Gram-positive and Gramnegative bacteria.
32,33 Therefore, it would be essential to monitor the intensity of antibiotic-mediated selection not only in clinical strains but also in intestinal and environmental strains, which are, in turn, potential exogenous pathogens. 34 Unfortunately, there has been little data on the natural frequency of antibiotic resistance genes in the normal anaerobic flora in Brazil. 35 The same applies to environmental strains whose analysis the present study reports for the first time. The strains with reduced susceptibility to meropenem, found in this study, appear to produce the cfiA-type metallo--lactamase. According to the literature, carbapenem resistance is related to this enzyme [8] [9] [10] [11] [12] which requires two tightly bound Zn 2ϩ ions for full activity. 36 This metal ion active site seems to be responsible for both the decreased susceptibility to -lactamase inhibitors and the capacity to hydrolyse a broad range of -lactams. Also, such enzyme was detected even before the widespread use of carbapenems. 37 As the cfiA gene has been detected in some clinical and environmental strains, and has also been found in transmissible determinants 9 the spread of antimicrobial resistance represents a threat, mainly in regions where policies on antibiotic use are not very strict. Although the -lactamase activities or alterations of membrane permeability have not been investigated, the screening of isolates by PCR with the primers synthesized from cfiA sequence represents a practical methodology which allows an estimation of the potential for the development of carbapenem resistance among B. fragilis strains. 
